These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
973 related articles for article (PubMed ID: 30105577)
1. Validation of the Oncomine Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577 [TBL] [Abstract][Full Text] [Related]
2. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material. de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633 [TBL] [Abstract][Full Text] [Related]
3. Validation and optimization of the Ion Torrent S5 XL sequencer and Oncomine workflow for BRCA1 and BRCA2 genetic testing. Shin S; Kim Y; Chul Oh S; Yu N; Lee ST; Rak Choi J; Lee KA Oncotarget; 2017 May; 8(21):34858-34866. PubMed ID: 28422718 [TBL] [Abstract][Full Text] [Related]
4. Use of the Ion AmpliSeq Cancer Hotspot Panel in clinical molecular pathology laboratories for analysis of solid tumours: With emphasis on validation with relevant single molecular pathology tests and the Oncomine Focus Assay. Lee A; Lee SH; Jung CK; Park G; Lee KY; Choi HJ; Min KO; Kim TJ; Lee EJ; Lee YS Pathol Res Pract; 2018 May; 214(5):713-719. PubMed ID: 29615338 [TBL] [Abstract][Full Text] [Related]
5. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing. Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646 [TBL] [Abstract][Full Text] [Related]
6. Validation of a next generation sequencing panel for detection of hotspot cancer mutations in a clinical laboratory. Shahsiah R; DeKoning J; Samie S; Latifzadeh SZ; Kashi ZM Pathol Res Pract; 2017 Feb; 213(2):98-105. PubMed ID: 28049581 [TBL] [Abstract][Full Text] [Related]
7. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. Mehrotra M; Duose DY; Singh RR; Barkoh BA; Manekia J; Harmon MA; Patel KP; Routbort MJ; Medeiros LJ; Wistuba II; Luthra R PLoS One; 2017; 12(8):e0181968. PubMed ID: 28767674 [TBL] [Abstract][Full Text] [Related]
8. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors. Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415 [TBL] [Abstract][Full Text] [Related]
10. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics. Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318 [TBL] [Abstract][Full Text] [Related]
11. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Hovelson DH; McDaniel AS; Cani AK; Johnson B; Rhodes K; Williams PD; Bandla S; Bien G; Choppa P; Hyland F; Gottimukkala R; Liu G; Manivannan M; Schageman J; Ballesteros-Villagrana E; Grasso CS; Quist MJ; Yadati V; Amin A; Siddiqui J; Betz BL; Knudsen KE; Cooney KA; Feng FY; Roh MH; Nelson PS; Liu CJ; Beer DG; Wyngaard P; Chinnaiyan AM; Sadis S; Rhodes DR; Tomlins SA Neoplasia; 2015 Apr; 17(4):385-99. PubMed ID: 25925381 [TBL] [Abstract][Full Text] [Related]
12. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691 [TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform. Vanni I; Coco S; Truini A; Rusmini M; Dal Bello MG; Alama A; Banelli B; Mora M; Rijavec E; Barletta G; Genova C; Biello F; Maggioni C; Grossi F Int J Mol Sci; 2015 Dec; 16(12):28765-82. PubMed ID: 26633390 [TBL] [Abstract][Full Text] [Related]
14. Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. Paasinen-Sohns A; Koelzer VH; Frank A; Schafroth J; Gisler A; Sachs M; Graber A; Rothschild SI; Wicki A; Cathomas G; Mertz KD Neoplasia; 2017 Mar; 19(3):196-206. PubMed ID: 28161563 [TBL] [Abstract][Full Text] [Related]
15. Implementation of an ISO15189 accredited next-generation sequencing service with the fully automated Ion Torrent Genexus: the experience of a clinical diagnostic laboratory. Werner R; Connolly A; Bennett M; Hand CK; Burke L J Clin Pathol; 2024 Mar; 77(4):278-283. PubMed ID: 36522176 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens. Haley L; Parimi V; Jiang L; Pallavajjala A; Hardy M; Yonescu R; Morsberger L; Stinnett V; Long P; Zou YS; Gocke CD J Mol Diagn; 2021 Oct; 23(10):1343-1358. PubMed ID: 34358677 [TBL] [Abstract][Full Text] [Related]
18. Targeted mutation detection in breast cancer using MammaSeq™. Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836 [TBL] [Abstract][Full Text] [Related]
19. Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing. Janaki N; Harbhajanka A; Michael CW; Bomeisl P; Wasman J; Atchley M; Miskiewicz K; Alouani D; Sadri N Cancer Cytopathol; 2019 May; 127(5):297-305. PubMed ID: 30933438 [TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of the AmpliSeq Cancer Hotspot panel v2 in combination with the Ion Torrent Next Generation Sequencing Personal Genome Machine. Butler KS; Young MY; Li Z; Elespuru RK; Wood SC Regul Toxicol Pharmacol; 2016 Feb; 74():178-86. PubMed ID: 26387931 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]